ArticleJCO precision oncology2025
Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast.
Article in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Assessing the utility of ctDNA as a prognostic marker in advanced ER-positive/HER2-negative breast cancer.Translational cancer research · 2026Article
- Phylogeography of Bone Metastasis: Clonal Evolution, Skeletal Niche Adaptation, and Clinical Implications.International journal of molecular sciences · 2026Review
- Identification of cancer mini-drivers by deciphering selective landscape in the cancer genome.Briefings in bioinformatics · 2026Article
- Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.Nature communications · 2025Article
- Multi-Biofluid Approaches for cftDNA and cftRNA Biomarker Detection: Advances in Early Cancer Detection and Monitoring.Current issues in molecular biology · 2025Review
- Comment on: Exploring the utility of ctDNA testing in high-risk breast cancer patients in a community setting: case series.Therapeutic advances in medical oncology · 2025Article
- Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma.The oncologist · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDespite varying treatment responses and vastly different clinicopathologic characteristics, invasive lobular carcinoma (ILC) is treated similar to other subtypes of breast cancer. Serial personalized and tumor-informed, circulating tumor DNA (ctDNA) analysis may enable real-time treatment monitoring in metastatic ILC (mILC).
methodsIn this retrospective analysis of real-world data, we analyzed ctDNA longitudinally in 66 patients with mILC using a clinically validated, personalized, tumor-informed 16-plex polymerase chain reaction-next generation sequencing assay (Signatera). We evaluated the predictive value on survival of a single ctDNA test result and correlated ctDNA detection rates and on-treatment ctDNA dynamics with disease status.
resultsA total of 355 plasma samples were analyzed from 66 patients with mILC (median age at diagnosis, 62.6 years [range, 32.2-79.7 years]). On treatment, ctDNA dynamics correlated well with clinical response to treatment as assessed by imaging. Ninety-two percent (11 of 12) of patients with either ctDNA decrease (6 of 6) or no change in ctDNA levels (5 of 6) while on treatment showed clinical benefit from their prescribed regimen, whereas only 31% (4 of 13) of patients who showed an increase in their ctDNA had a clinical benefit on imaging. Finally, patients with a positive ctDNA test showed a greater probability of death compared with those with negative results, and the positive predictive value of ctDNA testing continued to increase exponentially with each positive result. Similarly, a negative ctDNA result was associated with 97% overall survival at 6 months and remained high (approximately 90%) at the 12-month follow-up.
conclusionSerial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.